rkda-8k_20161109.htm

ARCADIA BIOSCIENCES, INC.

Date: November 9, 2016

/s/ WENDY S. NEAL

Wendy S. Neal

Vice President, Chief Legal Officer & Secretary

0001564590-16-028659.txt : 20161109 0001564590-16-028659.hdr.sgml : 20161109 20161109163017 ACCESSION NUMBER: 0001564590-16-028659 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161103 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20161109 DATE AS OF CHANGE: 20161109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arcadia Biosciences, Inc. CENTRAL INDEX KEY: 0001469443 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 810571538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37383 FILM NUMBER: 161984618 BUSINESS ADDRESS: STREET 1: 202 COUSTEAU PLACE STREET 2: SUITE 200 CITY: DAVIS STATE: X1 ZIP: 95618 BUSINESS PHONE: 602-429-0476 MAIL ADDRESS: STREET 1: 4222 E. THOMAS RD STREET 2: SUITE 320 CITY: PHOENIX STATE: X1 ZIP: 85018 8-K 1 rkda-8k_20161109.htm 8-K ANNOUNCING VIC KNAUF REITREMENT rkda-8k_20161109.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report: November 3, 2016

(Date of earliest event reported)

Arcadia Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-37383

81-0571538

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

202 Cousteau Place, Suite 105

Davis, CA 95618

(Address of principal executive offices, including zip code)

(530) 756-7077

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 3, 2016, Vic C. Knauf, Ph.D., Chief Scientific Officer of Arcadia Biosciences, Inc. (the “Company”) notified the Company of his intention to retire, effective as of December 31, 2016 (the “Effective Date”). After the Effective Date, Dr. Knauf will remain a Class II director on the Board of Directors of the Company.

Following the Effective Date, certain members of the management team and other senior employees will assume shared responsibility for the Chief Scientific Officer role and duties. Dr. Knauf will assist in an informal advisory capacity after the Effective Date to ensure a seamless transition of his management duties.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.